The proof of concept for the efficacy of BET inhibitors in NMC was further supported by a phase 1 study, with Molibresib (GSK525762) showing PR in 4 out of 19 patients (21%) and stable disease (SD) in 8 patients (42%) as the best response in patients affected by NMC [10]. Here, DNER is linked to nut midline carcinoma.